Regeneron Pharmaceuticals & European Union

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

European Union: The European Union considers the risk to its general public very low but has begun coordinating laboratory preparedness and traveler guidance through its Health Security Committee.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is the developer of Eylea, the reference product for Sun Pharma' newly launched biosimilar AHZANTIVE, which could lead to increased competition.

European Union: The European Commission approved AHZANTIVE in 2025, allowing its launch in European markets.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.

European Union: A spokesperson for the European Union>>> stated that the risk of an Ebola outbreak in Europe is 'very low', indicating monitoring of the situation but no immediate alarm for the region.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.